Publications by authors named "F Gaiani"
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFIntroduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to gather real-world data on the use of bimekizumab for treating moderate-to-severe plaque psoriasis in patients aged 65 and older, an age group often underrepresented in clinical trials.
- Conducted in 33 dermatological clinics in Italy, 98 elderly patients were treated with bimekizumab while collecting clinical and demographic data to monitor their progress and any adverse events over 36 weeks.
- Results showed significant improvements in psoriasis symptoms, with PASI scores dropping substantially after treatment, and a majority of patients achieving PASI75 or higher by weeks 16 and 36.